TY - JOUR
T1 - Redox-sensitive PEG-polypeptide nanoporous particles for survivin silencing in prostate cancer cells
AU - Cavalieri, Francesca
AU - Beretta, Giovanni L.
AU - Cui, Jiwei
AU - Braunger, Julia A.
AU - Yan, Yan
AU - Richardson, Joseph J.
AU - Tinelli, Stella
AU - Folini, Marco
AU - Zaffaroni, Nadia
AU - Caruso, Frank
PY - 2015/7/13
Y1 - 2015/7/13
N2 - We report the engineering of intracellular redox-responsive nanoporous poly(ethylene glycol)-poly(l-lysine) particles (NPEG-PLLs). The obtained particles exhibit no toxicity while maintaining the capability to deliver a small interfering RNA sequence (siRNA) targeting the anti-apoptotic factor, survivin, in prostate cancer cells. The redox-mediated cleavage of the disulfide bonds stabilizing the NPEG-PLL-siRNA complex results in the release of bioactive siRNA into the cytosol of prostate cancer PC-3 cells, which, in turn, leads to the effective silencing (∼59 ± 8%) of the target gene. These findings, obtained under optimal conditions, indicate that NPEG-PLLs may protect the therapeutic nucleic acid in the extracellular and intracellular environments, thus preventing the occurrence of competitive interactions with serum and cytosolic proteins as well as degradation by RNase. The intracellular trafficking and final fate of the NPEG-PLLs were investigated by a combination of deconvolution microscopy, fluorescence lifetime imaging microscopy, and super-resolution structured illumination microscopy. A significant impairment of cell survival was observed in cells concomitantly exposed to paclitaxel and siRNA-loaded NPEG-PLLs. Overall, our findings indicate that NPEG-PLLs represent a highly loaded depot for the delivery of therapeutic nucleic acids to cancer cells.
AB - We report the engineering of intracellular redox-responsive nanoporous poly(ethylene glycol)-poly(l-lysine) particles (NPEG-PLLs). The obtained particles exhibit no toxicity while maintaining the capability to deliver a small interfering RNA sequence (siRNA) targeting the anti-apoptotic factor, survivin, in prostate cancer cells. The redox-mediated cleavage of the disulfide bonds stabilizing the NPEG-PLL-siRNA complex results in the release of bioactive siRNA into the cytosol of prostate cancer PC-3 cells, which, in turn, leads to the effective silencing (∼59 ± 8%) of the target gene. These findings, obtained under optimal conditions, indicate that NPEG-PLLs may protect the therapeutic nucleic acid in the extracellular and intracellular environments, thus preventing the occurrence of competitive interactions with serum and cytosolic proteins as well as degradation by RNase. The intracellular trafficking and final fate of the NPEG-PLLs were investigated by a combination of deconvolution microscopy, fluorescence lifetime imaging microscopy, and super-resolution structured illumination microscopy. A significant impairment of cell survival was observed in cells concomitantly exposed to paclitaxel and siRNA-loaded NPEG-PLLs. Overall, our findings indicate that NPEG-PLLs represent a highly loaded depot for the delivery of therapeutic nucleic acids to cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=84937061164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937061164&partnerID=8YFLogxK
U2 - 10.1021/acs.biomac.5b00562
DO - 10.1021/acs.biomac.5b00562
M3 - Article
C2 - 26120930
AN - SCOPUS:84937061164
SN - 1525-7797
VL - 16
SP - 2168
EP - 2178
JO - Biomacromolecules
JF - Biomacromolecules
IS - 7
ER -